Your speculation that the MHRA might have issued a "stealth rejection" to Northwest Biotherapeutics (NWBO) that the company is sitting on, possibly indefinitely, reflects a misunderstanding of how the regulatory process works—especially under the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) procedures for Marketing Authorisation Applications (MAAs).
Here's what you're missing:
1. The MHRA Process Is Statutorily Structured and Time-Bound
Under the Human Medicines Regulations 2012 and subsequent updates, the MHRA operates under clear, mandated timelines and formal procedures for evaluating MAAs. These include:
A 210-day evaluation period (excluding clock-stops for requests for information (RFIs));
If the MHRA issues RFIs, the clock stops, and the applicant is given a specific deadline to respond—usually 3 to 6 months depending on the complexity;
If the applicant fails to respond or cannot resolve the issues, the MHRA may formally refuse the application with a written Rejection (Non-Approval) letter.
In other words: there is no such thing as an indefinite limbo. A regulator cannot let an application dangle unresolved forever.
2. Regulators Don’t “Informally Reject” Applications Without Record
The idea that the MHRA would issue an RFI with "impossible stipulations" just to subtly reject the application—but not document it formally—is simply not how modern drug regulation works. If the MHRA believes an application cannot be approved based on the data available, it will issue a formal decision—either:
A Refusal to Grant a Marketing Authorisation, or
A decision inviting resubmission under a new application.
Everything is documented. There are regulatory accountability standards, both for the agency and the sponsor.
3. Obligation to Disclose Material Information
Public companies, especially biotech firms like NWBO, are obligated under securities laws to disclose material regulatory outcomes. A formal rejection or even a clear signal that approval is unattainable would be material. If the MHRA gave NWBO a demand that was clearly impossible and indicated no path forward, NWBO would be obligated to disclose that to investors.
So your assertion that NWBO could “just sit on” a de facto rejection without consequence is legally and procedurally inaccurate.
4. Continued Engagement with MHRA Suggests the Process Is Ongoing
The company has stated that it is “engaged with the MHRA,” which—assuming it's truthful—means the MAA is still under review, likely under a clock-stop due to RFIs. That’s a normal and expected part of the review process, especially for complex or non-traditional data packages like NWBO’s.
In Summary:
The MHRA cannot indefinitely stall a decision without formal action.
"Impossible RFIs" used as stealth rejections do not exist as a regulatory practice.
NWBO would be legally required to disclose a de facto rejection.
The MAA is likely in a standard clock-stop period, awaiting response or resolution.
Speculating about imaginary "silent rejections" isn't just uninformed—it's misleading. If you're going to critique a company, it’s best to do so with a correct understanding of the regulatory framework.
Market Data 
Markets 
AI
